NCAM1 and neoplasm: Actually, periphery CD16-CD56 + bright/dim NK cells do not start with anti-tumor activity, but can rapidly proliferate and transform into CD16CD56+bright NK cells after stimulation by cytokines (IL-2, IL-12 and IL-15) to acquire anti-tumor cytotoxic capacity [35].